Bluebird Bio's Zynteglo Flies Through Its CHMP Review
Executive Summary
A nod in record time from the European Medicines Agency’s CHMP for its beta-thalassemia gene therapy Zynteglo pushes bluebird bio out of the nest and into commercial territory.
You may also be interested in...
Bluebird Pushes For Zynteglo Pricing Of Five €315K Annual Installments
CEO Nick Leschly talked to Scrip about the European payment strategy for the one-time gene therapy, which will cost €1.575m over five years if treatment is successful.
Roche Confident Spark Therapeutics Acquisition Will Complete In First Half
US financial regulators have not been quick at reviewing Roche’s multi-billion dollar acquisition of gene therapy biotech Spark Therapeutics, but it is still on track for completion in the first half of 2019.
EU Hat Trick For Bluebird’s Beta-Thalassemia Gene Therapy
bluebird bio is set to enter the EU market with the first gene therapy for transfusion-dependent β-thalassemia, after the European Medicines Agency reviewed its product in record time. Bluebird believes that the agency’s Priority Medicines (PRIME) and adaptive pathways programs have been instrumental in smoothing its path.